Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926.

PMID:
30745444
2.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31.

PMID:
30738748
3.

The Emerging Evidence of the Parkinson Pandemic.

Dorsey ER, Sherer T, Okun MS, Bloem BR.

J Parkinsons Dis. 2018;8(s1):S3-S8. doi: 10.3233/JPD-181474.

4.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

5.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

6.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

7.

Is Axonal Degeneration a Key Early Event in Parkinson's Disease?

Kurowska Z, Kordower JH, Stoessl AJ, Burke RE, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, Medicetty S.

J Parkinsons Dis. 2016 Oct 19;6(4):703-707. Review.

PMID:
27497486
8.

Parkinson's disease is ready for precision medicine.

Sherer TB, Frasier MA, Langston JW, Fiske BK.

Per Med. 2016 Sep;13(5):405-407. doi: 10.2217/pme-2016-0052. Epub 2016 Aug 9. No abstract available.

9.

Nilotinib - Differentiating the Hope from the Hype.

Wyse RK, Brundin P, Sherer TB.

J Parkinsons Dis. 2016 Jul 12;6(3):519-22. doi: 10.3233/JPD-160904.

10.

Neuroscience Training for the 21st Century.

Akil H, Balice-Gordon R, Cardozo DL, Koroshetz W, Posey Norris SM, Sherer T, Sherman SM, Thiels E.

Neuron. 2016 Jun 1;90(5):917-26. doi: 10.1016/j.neuron.2016.05.030. Review.

11.

Feasibility of Virtual Research Visits in Fox Trial Finder.

Dorsey ER, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdhury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, Biemiller RA, Biglan KM.

J Parkinsons Dis. 2015;5(3):505-15. doi: 10.3233/JPD-150549.

12.

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.

Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P, Lee DW, Lewin-Koh SC, Lin T, Liu X, Liu S, Lyssikatos JP, O'Mahony J, Reichelt M, Roose-Girma M, Sheng Z, Sherer T, Smith A, Solon M, Sweeney ZK, Tarrant J, Urkowitz A, Warming S, Yaylaoglu M, Zhang S, Zhu H, Estrada AA, Watts RJ.

Sci Transl Med. 2015 Feb 4;7(273):273ra15. doi: 10.1126/scitranslmed.aaa3634.

PMID:
25653221
13.

Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder.

Rocker C, Cappelletti L, Marshall C, Meunier CC, Brooks DW, Sherer T, Chowdhury S.

J Parkinsons Dis. 2015;5(1):55-66. doi: 10.3233/JPD-140522.

PMID:
25624422
14.

Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Choi DW, Armitage R, Brady LS, Coetzee T, Fisher W, Hyman S, Pande A, Paul S, Potter W, Roin B, Sherer T.

Neuron. 2014 Nov 5;84(3):554-63. doi: 10.1016/j.neuron.2014.10.027. Epub 2014 Nov 5. Review.

15.

Overcoming obstacles to repurposing for neurodegenerative disease.

Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM.

Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.

16.

The future of research in Parkinson disease.

Jankovic J, Sherer T.

JAMA Neurol. 2014 Nov;71(11):1351-2. doi: 10.1001/jamaneurol.2014.1717. Review. No abstract available.

PMID:
25178587
17.

MORE THAN MONEY: THE EXPONENTIAL IMPACT OF ACADEMIC TECHNOLOGY TRANSFER.

McDevitt VL, Mendez-Hinds J, Winwood D, Nijhawan V, Sherer T, Ritter JF, Sanberg PR.

Technol Innov. 2014 Nov 1;16(1):75-84.

18.

Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.

Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC 3rd, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, Goldberg MS, Benkovic SA, Haupt M, Baptista MA, Fiske BK, Sherer TB, Frasier MA.

Neurobiol Dis. 2014 Oct;70:190-203. doi: 10.1016/j.nbd.2014.06.009. Epub 2014 Jun 24.

19.

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF.

Mov Disord. 2014 May;29(6):772-9. doi: 10.1002/mds.25859. Epub 2014 Mar 7.

PMID:
24610195
20.

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.

Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK.

PLoS One. 2013 Nov 14;8(11):e80705. doi: 10.1371/journal.pone.0080705. eCollection 2013.

21.

A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research.

Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA.

Dis Model Mech. 2013 Nov;6(6):1316-24. doi: 10.1242/dmm.011940. Epub 2013 Sep 12.

22.

Money without collaboration won't bring cures.

Sherer TB.

Nat Med. 2013 Feb;19(2):127. doi: 10.1038/nm0213-127. No abstract available.

PMID:
23389601
23.

Overcoming obstacles in Parkinson's disease.

Sherer TB, Chowdhury S, Peabody K, Brooks DW.

Mov Disord. 2012 Nov;27(13):1606-11. doi: 10.1002/mds.25260. Epub 2012 Oct 31. Review.

PMID:
23115047
24.

Biomarkers for Parkinson's disease.

Sherer TB.

Sci Transl Med. 2011 Apr 20;3(79):79ps14. doi: 10.1126/scitranslmed.3002488.

PMID:
21508309
25.

Biomarkers in Parkinson's disease: a funder's perspective.

Frasier M, Chowdhury S, Eberling J, Sherer T.

Biomark Med. 2010 Oct;4(5):723-9. doi: 10.2217/bmm.10.89.

PMID:
20945984
26.

Funding of Parkinson research from industry and US federal and foundation sources.

Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H 3rd.

Mov Disord. 2009 Apr 15;24(5):731-7. doi: 10.1002/mds.22446.

PMID:
19133662
27.

Special focus section: gene therapy for Parkinson's disease.

Fiske BK, Frasier MA, Sherer TB.

Exp Neurol. 2008 Jan;209(1):28-9. Epub 2007 Sep 18. No abstract available.

PMID:
17980867
28.

Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease.

Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT.

J Neurochem. 2007 Mar;100(6):1469-79. Epub 2007 Jan 4.

29.

Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW.

Toxicol Sci. 2007 Jan;95(1):196-204. Epub 2006 Oct 12.

PMID:
17038483
30.

Crossroads in GDNF therapy for Parkinson's disease.

Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW.

Mov Disord. 2006 Feb;21(2):136-41.

PMID:
16470786
31.

Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT.

Neurobiol Dis. 2006 May;22(2):404-20. Epub 2006 Jan 24.

PMID:
16439141
32.

Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication.

Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT.

J Biol Chem. 2005 Dec 23;280(51):42026-35. Epub 2005 Oct 21.

33.

Paraquat neurotoxicity is distinct from that of MPTP and rotenone.

Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW.

Toxicol Sci. 2005 Nov;88(1):193-201. Epub 2005 Sep 1.

PMID:
16141438
34.

Oxidative damage in Parkinson's disease.

Sherer TB, Greenamyre JT.

Antioxid Redox Signal. 2005 May-Jun;7(5-6):627-9. No abstract available.

PMID:
15890006
35.

Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.

Testa CM, Sherer TB, Greenamyre JT.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):109-18. Epub 2005 Jan 6.

PMID:
15790535
36.

Ubiquitin-proteasome system and Parkinson's diseases.

Betarbet R, Sherer TB, Greenamyre JT.

Exp Neurol. 2005 Feb;191 Suppl 1:S17-27. Review.

PMID:
15629758
37.

Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.

Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, Casida JE.

Chem Res Toxicol. 2004 Nov;17(11):1540-8.

PMID:
15540952
38.
39.

Mechanism of toxicity in rotenone models of Parkinson's disease.

Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT.

J Neurosci. 2003 Nov 26;23(34):10756-64.

40.

The rotenone model of Parkinson's disease: genes, environment and mitochondria.

Greenamyre JT, Betarbet R, Sherer TB.

Parkinsonism Relat Disord. 2003 Aug;9 Suppl 2:S59-64. Review.

PMID:
12915069
41.

Pesticides and Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

ScientificWorldJournal. 2001 May 1;1:207-8. Review.

42.

Selective microglial activation in the rat rotenone model of Parkinson's disease.

Sherer TB, Betarbet R, Kim JH, Greenamyre JT.

Neurosci Lett. 2003 May 1;341(2):87-90.

PMID:
12686372
43.

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

Sherer TB, Kim JH, Betarbet R, Greenamyre JT.

Exp Neurol. 2003 Jan;179(1):9-16.

PMID:
12504863
44.

Mechanistic approaches to Parkinson's disease pathogenesis.

Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT.

Brain Pathol. 2002 Oct;12(4):499-510. Review.

PMID:
12408237
45.

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT.

J Neurosci. 2002 Aug 15;22(16):7006-15.

46.

Environment, mitochondria, and Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

Neuroscientist. 2002 Jun;8(3):192-7. Review.

PMID:
12061498
47.

Animal models of Parkinson's disease.

Betarbet R, Sherer TB, Greenamyre JT.

Bioessays. 2002 Apr;24(4):308-18. Review.

PMID:
11948617
48.

Complex I and Parkinson's disease.

Greenamyre JT, Sherer TB, Betarbet R, Panov AV.

IUBMB Life. 2001 Sep-Nov;52(3-5):135-41. Review.

49.

Pathogenesis of Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

Curr Opin Investig Drugs. 2001 May;2(5):657-62. Review.

PMID:
11569943
50.

Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells.

Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP Jr, Tuttle JB.

Brain Res. 2001 Feb 9;891(1-2):94-105.

PMID:
11164812

Supplemental Content

Loading ...
Support Center